These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32079989)

  • 1. Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease.
    Rivera-Rodriguez L; Pardo-Díaz E; Moreno-Espinosa S; Scheffler-Mendoza S; Ruiz-Ontiveros MA; Garrido-García LM; Iglesias-Amaya A; Yamazaki-Nakashimada MA
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e448-e451. PubMed ID: 32079989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
    Pilania RK; Jindal AK; Johnson N; Prithvi A; Vignesh P; Suri D; Rawat A; Gupta A; Singh S
    Rheumatology (Oxford); 2021 Jul; 60(7):3413-3419. PubMed ID: 33221920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage activation syndrome in Kawasaki disease.
    Mukherjee D; Pal P; Kundu R; Niyogi P
    Indian Pediatr; 2014 Feb; 51(2):148-9. PubMed ID: 24632699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kawasaki Disease Complicated With Macrophage Activation Syndrome: A Systematic Review.
    García-Pavón S; Yamazaki-Nakashimada MA; Báez M; Borjas-Aguilar KL; Murata C
    J Pediatr Hematol Oncol; 2017 Aug; 39(6):445-451. PubMed ID: 28562511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kawasaki disease complicated by aspergillosis under cyclosporine and infliximab.
    Honda K; Watanabe Y; Motegi S; Watanabe T; Ikeda H
    Pediatr Int; 2022 Jan; 64(1):e15300. PubMed ID: 35998140
    [No Abstract]   [Full Text] [Related]  

  • 6. Recent advances in the treatment of Kawasaki disease.
    Weng KP; Ou SF; Lin CC; Hsieh KS
    J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage activation syndrome in children with Kawasaki disease: diagnostic and therapeutic approaches.
    Han SB; Lee SY
    World J Pediatr; 2020 Dec; 16(6):566-574. PubMed ID: 32418074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab for the treatment of Kawasaki disease.
    Matsubara T
    Pediatr Int; 2018 Sep; 60(9):775. PubMed ID: 30255976
    [No Abstract]   [Full Text] [Related]  

  • 9. Macrophage activation syndrome in the acute phase of Kawasaki disease.
    Latino GA; Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    J Pediatr Hematol Oncol; 2010 Oct; 32(7):527-31. PubMed ID: 20485197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis].
    Servel AC; Vincenti M; Darras JP; Lalande M; Rodière M; Filleron A
    Arch Pediatr; 2012 Jul; 19(7):741-4. PubMed ID: 22652521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Intravenous Immunoglobulin-Resistant Kawasaki Disease With Yersinia enterocolitica Enterocolitis Successfully Treated With Cefotaxime Following Infliximab and Cyclosporine.
    Ohnishi T; Sato S; Kinoshita K; Takei H; Furuichi M; Uejima Y; Kawano Y; Hara T; Suganuma E
    J Pediatric Infect Dis Soc; 2021 Mar; 10(2):225-226. PubMed ID: 32328655
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of acute and refractory Kawasaki disease.
    Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab as a novel therapy for refractory Kawasaki disease.
    Weiss JE; Eberhard BA; Chowdhury D; Gottlieb BS
    J Rheumatol; 2004 Apr; 31(4):808-10. PubMed ID: 15088313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kawasaki disease: 40 years after the original report.
    Gedalia A
    Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.
    Lind-Holst M; Hartling UB; Christensen AE
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31383678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin.
    Youn Y; Kim J; Hong YM; Sohn S
    Pediatr Infect Dis J; 2016 Apr; 35(4):457-9. PubMed ID: 26673981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment for late-onset arthritis associated with Kawasaki disease.
    Matsubara K; Togawa M; Tada M; Kitaguchi A; Amo K
    Pediatr Int; 2022 Jan; 64(1):e15154. PubMed ID: 35412003
    [No Abstract]   [Full Text] [Related]  

  • 19. Procalcitonin levels predicting the infliximab response of immunoglobulin resistant Kawasaki disease.
    Nakashima Y; Nanishi E; Yamamura K; Uike K; Terashi E; Hirata Y; Nagata H; Morihana E; Tanaka T; Honjo S; Takada H; Ohga S
    Cytokine; 2019 Feb; 114():26-31. PubMed ID: 30583086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kawasaki Disease with Peripheral and Facial Gangrene: A Case report and review of literature.
    Madan D; Maheshwari A; Mahto D; Mendiratta V; Sharma S
    Trop Doct; 2022 Jul; 52(3):449-452. PubMed ID: 35345947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.